Specialties / Hepatology
New Hepatology research.
The strongest recent Hepatology papers on PubMed, ranked by study design, topic and journal, with the same summaries subscribers get.
-
retrospective cohort, 32,383 patients
Superior Efficacy of Besifovir in Reducing Hepatocellular Carcinoma Risk Compared to Tenofovir in Chronic Hepatitis B Patients: A Nationwide Cohort Study
Shin YE, Kim JY, Kim H, et al. J Korean Med Sci. Oct 2026.
- Findings
- In 32,383 chronic hepatitis B patients, propensity score-matched besifovir treatment was associated with lower HCC incidence (9.63 vs 15.36 per 1,000 person-years, P = 0.001) compared to tenofovir.
- Bottom line
- Besifovir may provide superior protection against hepatocellular carcinoma compared to tenofovir in chronic hepatitis B.
-
observational study, 8 cell lines and 519 patients
Hepatocellular Carcinoma Overcomes Lipid Depletion by Utilizing Serine for Phospholipid Synthesis and Enhanced Survival
Paul B, Lewinska M, Lafuente-Barquero JF, et al. JHEP Rep. Oct 2026.
- Findings
- In 8 cell lines and 519 patients with hepatocellular carcinoma, lipid-depletion resistant tumors adapted via serine utilization (P < 0.0001), which correlated with lower patient survival (P < 0.0001).
- Bottom line
- Early-stage science. Targeting lipid and serine metabolic pathways may offer new therapeutic options for hepatocellular carcinoma.
-
observational study, 656 patients
Beyond BCLC and AFP: A Circulating IL-6/IL-8 Inflammatory Signature Refines Survival Prediction in Hepatocellular Carcinoma
Guariglia M, Gaia S, Dileo E, et al. Immunology. Oct 2026.
- Findings
- In 656 hepatocellular carcinoma patients, baseline IL-6 (aHR = 2.01, p < 0.001) and IL-8 (aHR = 1.35, p = 0.033) predicted overall survival, improving model discrimination over BCLC and AFP (C-index 0.717, p < 0.001).
- Bottom line
- Circulating IL-6 and IL-8 refine prognostic stratification beyond standard staging systems in hepatocellular carcinoma.
-
randomized trial, 28 patients
Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis
Liu J, Garcia-Guevara F, Macnaughtan J, et al. Liver Int. Nov 2026.
- Findings
- In a randomized double‑blind trial, patients received YAQ001 4 g once daily. Outcomes were measured at baseline, after 4 weeks and 12 weeks. Antibiotic resistance genes fell significantly in the YAQ001 arm, and the drug blocked K. pneumoniae biofilm formation in vitro.
- Bottom line
- YAQ001 4 g daily reduced resistance genes and prevented K. pneumoniae biofilms over a 12‑week period.
-
randomized trial, 50 patients
Effects of Aerobic Exercise on Autonomic and Endothelial Function and Splanchnic Hemodynamics in Compensated Cirrhosis: RCT Study
Kittiprachakul S, Rangkla S, Kulaputana O, et al. Liver Int. Nov 2026.
- Findings
- In compensated cirrhosis, aerobic exercise significantly improved 6MWT compared with control (mean Δ = 32 m, IQR: 12.00-51.60 m, p < 0.01). Within the exercise group, portal vein volume flow increased significantly (median Δ = 350.66 mL/min, p = 0.003).
- Bottom line
- Aerobic training enhances functional walking capacity without major adverse events in compensated cirrhosis.
-
randomized trial, 100 patients
Application of a nursing care bundle combined with a clinical nursing pathway in liver transplantation and its impact on patient self-management: a randomized controlled trial
Shi L, Lei Z, Wang S, et al. Langenbecks Arch Surg. Jul 2026.
- Findings
- A structured nursing bundle significantly improved postoperative biochemical outcomes, self-management scores, and medication adherence compared to routine care (P < 0.05). Psychological distress scores were also reduced (P < 0.05).
- Bottom line
- Integrating care bundles into clinical nursing pathways enhances self-care, laboratory markers, and quality of life after liver transplantation.
-
randomized trial, 802 patients
Patients with MASH experience worse health-related quality of life: a multinational real-world study using LiverMultiScan
Shumbayawonda E, Utsav M, Hancock M, et al. Qual Life Res. Oct 2026.
- Findings
- In the RADIcAL‑1 trial of 802 participants, baseline EQ‑5D utilities varied from 0.81 to 0.90 and fell to 0.82‑0.90 at 12 months. High‑risk MASH patients reported up to 12% more complaints, and each increase in cT1 raised anxiety/depression odds by 29%.
- Bottom line
- Among 802 patients, MASH is linked to up to 12% lower quality‑of‑life scores and a 29% higher chance of anxiety/depression, underscoring its greater clinical burden.
-
phase iii trial
Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma
Rimassa L, Dayyani F, Kelley RK, et al. Liver Cancer. Jul 2026.
- Findings
- In the HIMALAYA trial, STRIDE produced a 48‑month OS of 28.0% for patients with cardiovascular comorbidities and 20.4% for those with metabolic comorbidities, with long‑term survival in 28.2% and 22.6% respectively.
- Bottom line
- STRIDE provides comparable 48‑month OS whether or not patients have cardiovascular (28.0%) or metabolic (20.4%) comorbidities, and long‑term survival in about a quarter of each subgroup.
Summaries are written by AI from PubMed abstracts, for keeping up with the literature. Check the source before it changes care. Editorial policy · Medical disclaimer
Get Hepatology research every morning.
Free. Choose your Hepatology topics after you subscribe.